Go back to News
NEWS
GA_P advises Impact Partners on Top Doctors Series B financing round
Gómez-Acebo & Pombo has advised Impact Partners on its investment in Top Doctors. The Series B financing round, led by Impact Partners and in which the Institut Català de Finances (ICF) also participated, amounted to €11.2 million.
Top Doctors is a startup that offers a digital tool that allows users to access more than 90,000 experts in 50 medical specialties, while providing healthcare professionals with telemedicine solutions, online presence and brand image. The company expects to close the year with a turnover of 16 million euros, 30% more than in 2020. The capital increase will allow the company to consolidate its medical platform in the countries where it already operates in Europe, Latin America and the Middle East.
The GA_P team was formed by Álvaro Mateo and Rocío García de Oteyza, partner and associate in the Corporate area.
See complete article in CincoDías
Top Doctors is a startup that offers a digital tool that allows users to access more than 90,000 experts in 50 medical specialties, while providing healthcare professionals with telemedicine solutions, online presence and brand image. The company expects to close the year with a turnover of 16 million euros, 30% more than in 2020. The capital increase will allow the company to consolidate its medical platform in the countries where it already operates in Europe, Latin America and the Middle East.
The GA_P team was formed by Álvaro Mateo and Rocío García de Oteyza, partner and associate in the Corporate area.
See complete article in CincoDías
Lawyer mentioned
Álvaro Mateo Sixto – Partner
Category
Deal
Press contact

Sandra Cuesta
Director of Business Development, Marketing and Communications

Sandra Cuesta
Director of Business Development, Marketing and Communications
More information about
Gómez-Acebo & Pombo
PUBLICATION
2 days ago
Contractual termination by mutual abandonment not claimed by any party?
The risks of applying the doctrine according to which a contract is deemed withdrawn from if neither party to the same appears to want it. Not only is this solution likely to be inconsistent with the parties' claims, but it also wrongly rules out other civil law options the parties could pursue upon dismissal of the action for declaration of termination.
PUBLICATION
25 Sep, 2025
Pharma & Healthcare No. 45
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
PUBLICATION
05 Aug, 2025
Automotive and Sustainable Mobility No. 27
Summary of legislative and jurisprudential developments relating to the automotive sector.
PUBLICATION
30 Jul, 2025
Absolute prohibitions on pharmacy advertising are contrary to EU law
In its judgment of 19 June 2025 (European Commission v Republic of Poland, C‑200/24, ECLI:EU:C:2025:459), the Court of Justice has held that the introduction by national legislation of a total prohibition on advertising for pharmacies infringes European Union law.
PUBLICATION
09 Jul, 2025
Once again on the obligations assumed by the signers of a "strong" comfort letter
PUBLICATION
02 Jul, 2025
Pharma & Healthcare No. 44
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
PUBLICATION
19 Jun, 2025
Company resolutions reached with invalid votes
Although Article 204(3)(d) places them on the same level, the erroneous counting of votes and the counting of invalid votes are very different, given that the latter requires judicial balancing.
PUBLICATION
12 May, 2025
Automotive and Sustainable Mobility No. 26
Summary of legislative and case law developments in the automotive sector.
PUBLICATION
16 Apr, 2025
Pharma & Healthcare No. 43
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.